- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04407689
InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort (ILIAD-7-FR)
March 30, 2022 updated by: Revimmune
A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection in France and Belgium
Comparison of the effects of CYT107 vs Placebo administered IM at 10μg/ kg twice a week for two weeks on immune reconstitution of lymphopenic COVID-19 patients.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
Approximately forty-eight (48) participants will be randomized 1:1 to receive (a) Intramuscular (IM) administration of CYT107 at 3 μg/kg followed, after 48hrs of observation, by 10 μg/kg twice a week for 2 weeks or (b) Intramuscular (IM) placebo (normal saline) at the same frequency.
An interim safety review took place after the first 12 patients.
Since the CYT107 was well tolerated, the test dose (3 μg/kg) ceased and the initial dose became the same as the rest of the doses (10 μg/kg).
So, the remaining patients will be randomized to receive 5 administrations of (a) CYT107 at 10 μg/kg every 3 to 4 days for 2 weeks or (b) Intramuscular (IM) placebo (normal saline) at the same frequency.
The aim of the study is to test the ability of CYT107 to produce an immune reconstitution of these patients and observe possible association with a clinical improvement
Study Type
Interventional
Enrollment (Actual)
34
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Limoges, France, 87042
- University Hospital of Limoges
-
Lyon, France, 69003
- Hôpital Edouard Herriot
-
Lyon, France, 69437
- Hôpital Edouard Herriot
-
Orléans, France, 45067
- CHR Orléans La Source
-
Paris, France, 75014
- Hopital Cochin
-
Tours, France, 37000
- CHRU Tours
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
25 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- A written, signed informed consent, or emergency oral consent, by the patient or the patient's legally authorized representative, and the anticipated ability for participant to be re-consented in the future for ongoing Study participation
- Men and women aged ≥ 25 - 80 (included) years of age
- Hospitalized patients with one absolute lymphocyte count (ALC) ≤ 1000 cells/mm3, collected at baseline or no more than 72h before baseline
- Hospitalized patients with moderate to severe hypoxemia requiring oxygen therapy at >4L per minute nasal cannula or greater to keep saturations >90%, non-invasive positive pressure ventilation (e.g., BIPAP) for respiratory failure
- Confirmed infection with COVID-19 by any acceptable test available/ utilized at each site
- Patient with medical insurance or government support
Exclusion Criteria:
- Pregnancy or breast feeding;
- Refusal or inability to practice contraception regardless of the gender of the patient;
- ALT and/or AST > 5 x ULN
- Known, active auto-immune disease;
- Ongoing cancer treatment with chemotherapy / immunotherapy or any cancer therapy within last 3 months and/or ongoing;
- Patients with past history of Solid Organ transplant.
- Active tuberculosis, uncontrolled active HBV or HCV infection, HIV with positive viral load.
Patients whose respiratory condition is showing significant deterioration as indicated by:
- 8a requirement for an increase in inspired oxygen concentrations of 20% or more over the past 24 hours to maintain SpO2 at greater than or equal to 88%
- 8b or need for invasive mechanical ventilation
- Patients showing an increase of the NEWS2 score by more than 6 points during the screening / baseline period (48 to 72 hrs prior to first administration)
- Patients with chronic kidney dialysis
- Patients with a SOFA score ≥ 9 at baseline
- Patients with a BMI > 40
- Patients receiving any agent with immune suppressive effects,such as anti-IL6 treatments like Tocilizumab or Sarilumab which should preferably be minimized
- Presence of any of the following abnormal laboratory values at screening: absolute neutrophil count (ANC) < 1.5x109/L, Platelets < 50,000 per mm3
- Patients with uncontrolled pre-existing severe major organ dysfunction (cardiac, liver or renal failure)
- Vaccination with live attenuated vaccines in the month preceding the inclusion
- Use of chronic oral corticosteroids ≥ 10mg prednisone equivalent a day for a non-COVID-19 related condition
- Patients with baseline Rockwood Clinical Frailty Scale ≥ 6.
- Patients with known hypersensitivity to natural or recombinant Interleukin-7 or to any of the excipients
- Patients under guardianship
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CYT107
Intra-muscular administration of CYT107 twice a week for a total of 5 administrations
|
Intramuscular (IM) administration of CYT107 at 3 μg/ kg followed, after 48hrs of observation, by 10 μg/kg twice a week for 2 weeks or
Other Names:
|
Placebo Comparator: Saline
Intramuscular (IM) administration of saline at the same volume and same time for a total of 5 administrations
|
Intramuscular (IM) placebo (normal saline) at the same frequency
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement of the absolute lymphocyte count (ALC) of lymphopenic (ALC≤1000/mm3) COVID-19 infected participants out to approximately 30 days following initial Study drug administration or Hospital discharge (HD), whichever occurs first
Time Frame: 1 month
|
A statistically significant increase of the absolute lymphocyte count (ALC) from randomization to day 30 or Hospital Discharge
|
1 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
a significant decline of SARS-CoV-2 viral load through day 30 or HD
Time Frame: 1 month or HD (whichever occurs first)
|
The decrease of SARS-CoV-2 viral load from measurements at baseline and days of treatment dose 4 and dose 5, Day 21 and Day 30 or HD (whichever occurs first)
|
1 month or HD (whichever occurs first)
|
length of hospitalization compared to placebo arm
Time Frame: 45 days
|
Number of days of hospitalization during index hospitalization (defined as time from initial Study drug treatment through HD)
|
45 days
|
length of stay in ICU compared to placebo arm
Time Frame: 45 days
|
Number of days in ICU during index hospitalization
|
45 days
|
number of readmissions to ICU compared to placebo arm
Time Frame: 45 days
|
Readmissions to ICU through Day 45
|
45 days
|
organ support free days compared to placebo arm
Time Frame: 45 days
|
Organ support free days (OSFDs) during index hospitalization (This includes ventilator assistance free days)
|
45 days
|
Frequency of re-hospitalization through day 45 compared to placebo arm
Time Frame: 45 days
|
Number of readmissions to the hospital through Day 45
|
45 days
|
All-cause mortality through day 45 compared to placebo arm
Time Frame: 45 days
|
All-cause mortality through Day 45
|
45 days
|
level of other known biomarkers of inflammation: Ferritin compared to placebo arm
Time Frame: 30 days
|
Track and evaluate other known biomarkers of inflammation, Ferritin, from baseline to day 30
|
30 days
|
Level of other known biomarkers of inflammation: CRP compared to placebo arm
Time Frame: 30 days
|
Track and evaluate other known biomarkers of inflammation, CRP from baseline to day 30
|
30 days
|
Level of other known biomarkers of inflammation: D-dimer compared to placebo arm
Time Frame: 30 days
|
Track and evaluate other known biomarkers of inflammation, D-dimer from baseline to day 30
|
30 days
|
Physiological status through NEWS2 evaluation compared to Placebo arm
Time Frame: 30 days
|
Evaluate improvement of the NEWS2 score value.
Score form 0 to 4: NO Risk Score of 7 or more: High risk
|
30 days
|
To obtain "clinical improvement" as defined by an improvement in a 11-points WHO score for Clinical Assessment, through day 30 or HD.
Time Frame: 1 month
|
to determine if CYT107 will improve the clinical status of hospitalized COVID-19 patients as measured by 11 steps WHO clinical improvement score
|
1 month
|
frequency of secondary infections through day 45 compared tp placebo arm
Time Frame: 45 days
|
Incidence of secondary infections based on pre-specified criteria as adjudicated by the Secondary Infections Committee (SIC) through Day 45
|
45 days
|
CD4+ and CD8+ T cell counts compared to placebo arm
Time Frame: 30 days
|
Absolute numbers of CD4+ and CD8+ T-cell counts at timepoints indicated on the Schedule of Activities (SoA) through Day 30 or HD
|
30 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety assessment through incidence and scoring of grade 3-4 adverse events
Time Frame: 45 days
|
Incidence and scoring of all grade 3-4 adverse events through Day 45 (using CTCAE Version 5.0 to assess severity)
|
45 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Bruno François, MD, University Hospital, Limoges
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11. Erratum In: Lancet. 2020 Mar 28;395(10229):1038. Lancet. 2020 Mar 28;395(10229):1038.
- Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585. Erratum In: JAMA. 2021 Mar 16;325(11):1113.
- Francois B, Jeannet R, Daix T, Walton AH, Shotwell MS, Unsinger J, Monneret G, Rimmele T, Blood T, Morre M, Gregoire A, Mayo GA, Blood J, Durum SK, Sherwood ER, Hotchkiss RS. Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial. JCI Insight. 2018 Mar 8;3(5):e98960. doi: 10.1172/jci.insight.98960.
- Venet F, Foray AP, Villars-Mechin A, Malcus C, Poitevin-Later F, Lepape A, Monneret G. IL-7 restores lymphocyte functions in septic patients. J Immunol. 2012 Nov 15;189(10):5073-81. doi: 10.4049/jimmunol.1202062. Epub 2012 Oct 10.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 8, 2020
Primary Completion (Actual)
March 30, 2022
Study Completion (Actual)
March 30, 2022
Study Registration Dates
First Submitted
May 27, 2020
First Submitted That Met QC Criteria
May 28, 2020
First Posted (Actual)
May 29, 2020
Study Record Updates
Last Update Posted (Actual)
April 8, 2022
Last Update Submitted That Met QC Criteria
March 30, 2022
Last Verified
March 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Hematologic Diseases
- Leukopenia
- Leukocyte Disorders
- COVID-19
- Lymphopenia
Other Study ID Numbers
- CLI107 COVID FR (ILIAD-7-FR)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
publication
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
First Affiliated Hospital Xi'an Jiaotong UniversityShangluo Central Hospital; Ankang Central Hospital; Hanzhong Central Hospital; Yulin... and other collaboratorsRecruitingCOVID-19 | Post-COVID-19 Syndrome | Post-Acute COVID-19 | Acute COVID-19China
Clinical Trials on Interleukin-7
-
Cytheris, Inc.CompletedAML | MDS | CMLUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAcute Myeloid Leukemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Cord Blood Transplant RecipientUnited States
-
Centre Leon BerardMinistry of Health, France; Cytheris, Inc.Completed
-
Cytheris SACompletedHIV Infections | LymphopeniaUnited States, France, Canada, Italy
-
Cytheris SATerminated
-
National Institutes of Health Clinical Center (CC)National Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
RevimmuneC.R.O. ReSolution Latin America S.A.TerminatedCOVID-19 | LymphocytopeniaBrazil
-
RevimmuneM.D. Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Cancer Research... and other collaboratorsTerminatedCOVID-19 | LymphocytopeniaUnited States
-
RevimmuneWashington University School of MedicineTerminatedMycobacterium Infections, NontuberculousUnited States
-
RevimmuneWashington University School of Medicine; Amarex Clinical ResearchTerminatedCOVID-19 | LymphocytopeniaUnited States